Jennifer Greggain
Nurse Practitioner · Channahon, ILNPI 1356779318
Payments from drug & device makers
Across 140 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$459
- Insulet Corporation$200
- Sanofi-aventis U.S. LLC$173
- Lilly USA, LLC$162
- Boehringer Ingelheim$155
- plus $1K from 33 others
What the payments were for
- Travel & lodging$1,05027%
- Food & beverage$2,90973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 11 | $1,326 |
| Novo Nordisk | 21 | $459 |
| Insulet Corporation | 9 | $200 |
| Sanofi-aventis U.S. LLC | 12 | $173 |
| Lilly USA, LLC | 7 | $162 |
| Boehringer Ingelheim | 8 | $155 |
| EMD Serono, Inc. | 5 | $144 |
| AstraZeneca(2 entities) | 9 | $143 |
| Amgen | 5 | $119 |
| AbbVie | 5 | $110 |
| Dexcom, Inc. | 5 | $95 |
| Corcept Therapeutics | 4 | $87 |
| Jazz Pharmaceuticals Inc. | 3 | $74 |
| Acorda Therapeutics, Inc | 3 | $73 |
| Abbott | 4 | $68 |
| Radius Health, Inc. | 1 | $51 |
| Recordati_rare_diseases_inc. | 2 | $49 |
| Sequel Med Tech, LLC | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Merck | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Averitas Pharma Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| UCB, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Argenx US, Inc. | 1 | $20 |
| Banner Life Sciences, LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
| Cequr Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,021
How this compares
$3,959 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 443 | $802,614 |
| JardianceEmpagliflozin | 196 | $295,885 |
| FarxigaDapagliflozin Propanediol | 197 | $256,687 |
| MounjaroTirzepatide | 167 | $212,668 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 101 | $148,210 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $114,244 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 45 | $94,164 |
| TrulicityDulaglutide | 51 | $86,281 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $71,629 |
| RybelsusSemaglutide | 45 | $57,159 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $56,200 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $53,283 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $52,275 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $35,583 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 221 | $31,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $459 | $867,376507 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $162 | $306,693240 claims |
| Boehringer IngelheimJardiance | $155 | $295,885196 claims |
| AstraZenecaFarxiga | $143 | $256,687197 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $173 | $148,210101 claims |
| MerckJanuvia | $30 | $15,89216 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $3,189317 claims |
| AbbVieSynthroid | $110 | $54727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.
Other nurse practitioner in Channahon
- Stefanie HenlineChannahon$17K
- Erika VuckoChicago$417K
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Kristy LukeChicago$77K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.